Otsuka Pharmaceutical Co. Ltd., of Tokyo, and its Canadian affiliate said Health Canada approved Jinarc (tolvaptan), a selective vasopressin V2-receptor antagonist, as the first pharmaceutical agent to treat autosomal dominant polycystic kidney disease.